Werewolf Therapeutics Q1 net loss narrows as expenses fall
Werewolf Therapeutics, Inc. HOWL | 0.00 |
Overview
U.S. biopharmaceutical firm's Q1 net loss narrowed yr/yr as operating expenses declined
Company entered asset purchase agreement with Jazz Pharmaceuticals for IFNα program
All obligations under loan agreement with K2 HealthVentures repaid after quarter end
Outlook
Company plans to update cash runway guidance in the near future
Result Drivers
LOWER R&D SPENDING - Q1 research and development expenses declined yr/yr, contributing to narrower net loss
Company press release: ID:nGNX4PxJl1
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q1 Net Income |
|
-$13.53 mln |
|
Q1 Basic EPS |
|
-$0.28 |
|
Q1 Operating Expenses |
|
$13.27 mln |
|
Q1 Operating Income |
|
-$13.27 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Werewolf Therapeutics Inc is $7.00, about 976.6% above its May 6 closing price of $0.65
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.